Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers

Evidence demonstrated that bones, liver, and lungs are the most common metastasis sites in some human malignancies, especially in prostate and breast cancers. Bone is the third most frequent target for spreading tumor cells among these organs and tissues. Patients with bone-metastatic cancers face a grim prognosis characterized by short median survival time. Current treatments have proven insufficient, as they can only inhibit metastasis or tumor progression within the bone tissues rather than providing a curative solution. Gaining a more profound comprehension of the interplay between tumor cells and the bone microenvironment (BME) is of utmost importance in tackling this issue. This knowledge will pave the way for developing innovative diagnostic and therapeutic approaches. This review summarizes the mechanisms underlying bone metastasis and discusses the clinical aspects of this pathologic condition. Additionally, it highlights emerging therapeutic interventions aimed at enhancing the quality of life for patients affected by bone-metastatic cancers. By synthesizing current research, this review seeks to shed light on the complexities of bone metastasis and offer insights for future advancements in patient care.

[1]  Xu Zhang,et al.  The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review , 2023, Frontiers in oncology.

[2]  Wei Guo,et al.  Chromatin accessibility dynamics in colorectal cancer liver metastasis: uncovering the liver tropism at single cell resolution. , 2023, Pharmacological research.

[3]  Hailin Tang,et al.  Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer , 2023, Molecular Cancer.

[4]  Shota Katayama,et al.  Targeting c-Jun is a potential therapy for luminal breast cancer bone metastasis. , 2023, Molecular cancer research : MCR.

[5]  Zhifu Yang,et al.  Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression. , 2023, Acta biomaterialia.

[6]  T. Nishimura,et al.  Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312). , 2023, Lung cancer.

[7]  Bixiang Zhang,et al.  Bone Lesion‐Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5‐Targeting miR‐3190‐5p , 2023, Advanced science.

[8]  Wenhao Zhou,et al.  Targeting nano-regulator based on metal–organic frameworks for enhanced immunotherapy of bone metastatic prostate cancer , 2023, Cancer Nanotechnology.

[9]  Min Wang,et al.  BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer , 2023, Journal for ImmunoTherapy of Cancer.

[10]  T. Yamashita,et al.  Sclerostin blockade promotes bone metastases of Wnt‐responsive breast cancer cells , 2023, Cancer science.

[11]  Baotong Zhang,et al.  Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer , 2023, BMC Medicine.

[12]  Yue Chen,et al.  Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases. , 2023, Molecular pharmaceutics.

[13]  H. Wakiyama,et al.  Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  Xiaorong Yang,et al.  Identification of miR-1-3p, miR-143-3p and miR-145-5p association with bone metastasis of Gleason 3+4 prostate cancer and involvement of LASP1 regulation. , 2023, Molecular and cellular probes.

[15]  E. V. Van Allen,et al.  A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). , 2023, Molecular cancer therapeutics.

[16]  Serk In Park,et al.  Circulating biomarkers for diagnosis and therapeutic monitoring in bone metastasis , 2023, Journal of Bone and Mineral Metabolism.

[17]  E. Denisov,et al.  Metastasis prevention: How to catch metastatic seeds. , 2023, Biochimica et biophysica acta. Reviews on cancer.

[18]  Lingfeng Zhu,et al.  Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment , 2023, Experimental Hematology & Oncology.

[19]  L. Jian,et al.  GPR84 potently inhibits osteoclastogenesis and alleviates osteolysis in bone metastasis of colorectal cancer , 2023, Journal of Orthopaedic Surgery and Research.

[20]  Wenlian Chen,et al.  Exosomal lncRNA HOTAIR promotes osteoclast differentiation by targeting TGF‐β/PTHrP/RANKL pathway , 2022, Basic & clinical pharmacology & toxicology.

[21]  M. Liaghat,et al.  The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors , 2022, Cell Communication and Signaling.

[22]  R. Motzer,et al.  Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade , 2022, Nature Reviews Urology.

[23]  Y. Lv,et al.  Combining dual-targeted liquid metal nanoparticles with autophagy activation and mild photothermal therapy to treat metastatic breast cancer and inhibit bone destruction. , 2022, Acta biomaterialia.

[24]  J. Pretell-Mazzini,et al.  Management of Long Bones Metastatic Disease: Concepts That We All Know but Not Always Remember , 2022, Orthopedic research and reviews.

[25]  Y. Zhang,et al.  SPON2 promotes the bone metastasis of lung adenocarcinoma via activation of the NF-κB signaling pathway. , 2022, Bone.

[26]  K. Russell,et al.  Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial. , 2022, JAMA oncology.

[27]  G. Hu,et al.  IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer , 2022, The Journal of clinical investigation.

[28]  P. Ha,et al.  The Role of ECM Remodeling, EMT, and Adhesion Molecules in Cancerous Neural Invasion: Changing Perspectives , 2022, Advanced biology.

[29]  Saman Maleki Vareki,et al.  Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy , 2022, Cancers.

[30]  Katsuhiro Hayashi,et al.  The role of surgery in the treatment of metastatic bone tumor , 2022, International Journal of Clinical Oncology.

[31]  Hyunsook Kim,et al.  RANKL biology. , 2022, Bone.

[32]  B. Ruszkowska-Ciastek,et al.  Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View , 2022, Biomedicines.

[33]  L. Strigari,et al.  Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis , 2022, Clinical and Translational Oncology.

[34]  M. Barcellos-Hoff,et al.  Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment , 2021, Molecular oncology.

[35]  A. Grumezescu,et al.  Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review , 2021, Cancers.

[36]  Libing Song,et al.  Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling , 2021, Molecular Cancer.

[37]  Huile Gao,et al.  Self‐Delivered Supramolecular Nanomedicine with Transformable Shape for Ferrocene‐Amplified Photodynamic Therapy of Breast Cancer and Bone Metastases , 2021, Advanced Functional Materials.

[38]  Xiaoyu Xu,et al.  Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer , 2021, Nature Communications.

[39]  Liang Liu,et al.  Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts , 2021, Cell Death & Disease.

[40]  K. Harada,et al.  Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study , 2021, International journal of urology : official journal of the Japanese Urological Association.

[41]  H. Tseng,et al.  The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma , 2021, Cancers.

[42]  Bin Bao,et al.  The hidden secrets of soluble RANKL in bone biology. , 2021, Cytokine.

[43]  P. Sarret,et al.  The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers , 2021, Cancer and Metastasis Reviews.

[44]  L. Hofbauer,et al.  Novel approaches to target the microenvironment of bone metastasis , 2021, Nature Reviews Clinical Oncology.

[45]  C. Ieranò,et al.  CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment , 2021, Frontiers in Oncology.

[46]  S. Achilefu,et al.  Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases , 2021, Molecular Cancer Therapeutics.

[47]  P. Troncoso,et al.  Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment , 2021, Clinical Cancer Research.

[48]  Lily Yang,et al.  Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer , 2021, Nature Communications.

[49]  A. Gangi,et al.  Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study. , 2021, Radiology. Imaging cancer.

[50]  L. Qin,et al.  Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways , 2021, Molecular Biomedicine.

[51]  D. Song,et al.  Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer , 2021, Clinical Cancer Research.

[52]  Yuanming Li,et al.  MP46-18 PATIENTS REPORT SATISFACTION/REGRET FOLLOWING FOCAL THERAPY FOR LOCALIZED PROSTATE CANCER: A PROSPECTIVE MULTICENTER EVALUATION , 2021, International Journal of Clinical Oncology.

[53]  J. Massagué,et al.  Targeting metastatic cancer , 2021, Nature Medicine.

[54]  K. Mortezaee,et al.  Steps in metastasis: an updated review , 2021, Medical Oncology.

[55]  Shukuan Ling,et al.  Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells , 2021, Theranostics.

[56]  Yayi He,et al.  Current progress and mechanisms of bone metastasis in lung cancer: a narrative review , 2021, Translational lung cancer research.

[57]  C. Moinpour,et al.  Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. , 2020, JAMA oncology.

[58]  Yi Shi,et al.  The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer , 2020, Frontiers in Pharmacology.

[59]  E. Danen,et al.  Metastasis: crosstalk between tissue mechanics and tumour cell plasticity , 2020, British Journal of Cancer.

[60]  Xiaoyu Xu,et al.  Bone-targeted oxidative stress nanoamplifier for synergetic chemo/chemodynamic therapy of bone metastases through increasing generation and reducing elimination of ROS , 2020 .

[61]  Jonathan M. Morris,et al.  Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. , 2020, Journal of vascular and interventional radiology : JVIR.

[62]  J. Marchal,et al.  Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment , 2020, Journal of Hematology & Oncology.

[63]  R. M. Pillai,et al.  Transitional dynamics of cancer stem cells in invasion and metastasis , 2020, Translational oncology.

[64]  C. Klein Cancer progression and the invisible phase of metastatic colonization , 2020, Nature Reviews Cancer.

[65]  B. Durden,et al.  Therapy Resistance, Cancer Stem Cells and ECM in Cancer: The Matrix Reloaded , 2020, Cancers.

[66]  Jianru Xiao,et al.  Targeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges. , 2020, Biomaterials.

[67]  Wei Li,et al.  Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis , 2020, International Journal of Clinical Pharmacy.

[68]  H. Cai,et al.  Bone-targeting polymer vesicles for simultaneous imaging and effective malignant bone tumor treatment. , 2020, Biomaterials.

[69]  I. Zalaudek,et al.  Diagnosis and treatment of melanoma bone metastasis: A multidisciplinary approach , 2020, Dermatologic therapy.

[70]  J. Pollard,et al.  Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth , 2020, The Journal of experimental medicine.

[71]  Yuan Luo,et al.  Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. , 2020, International journal of biological macromolecules.

[72]  C. Mandal Osteolytic metastasis in breast cancer: effective prevention strategies , 2020, Expert review of anticancer therapy.

[73]  Yuquan Wei,et al.  Molecular mechanisms and clinical management of cancer bone metastasis , 2020, Bone Research.

[74]  Zhen Zhao,et al.  Automated diagnosis of bone metastasis based on multi-view bone scans using attention-augmented deep neural networks , 2020, Medical Image Anal..

[75]  Shian-Ren Lin,et al.  Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis , 2020, Molecules.

[76]  N. Mao,et al.  A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients. , 2020, European journal of radiology.

[77]  V. Goh,et al.  Molecular Imaging of Bone Metastases and Their Response to Therapy , 2020, The Journal of Nuclear Medicine.

[78]  A. Verma,et al.  PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling. , 2020, Biochemical pharmacology.

[79]  Y. Wan,et al.  Differential regulation of breast cancer bone metastasis by PARP1 and PARP2 , 2020, Nature Communications.

[80]  M. Fares,et al.  Molecular principles of metastasis: a hallmark of cancer revisited , 2020, Signal Transduction and Targeted Therapy.

[81]  S. Dong,et al.  Sphingosine‐1‐phosphate (S1P) receptors: Promising drug targets for treating bone‐related diseases , 2020, Journal of cellular and molecular medicine.

[82]  G. Yin,et al.  Endogenous parathyroid hormone (PTH) signals through osteoblasts via RANKL during fracture healing to affect osteoclasts. , 2020, Biochemical and biophysical research communications.

[83]  Hsin-Hung Chen,et al.  Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. , 2020, Journal of materials chemistry. B.

[84]  Xiangchun Zhang,et al.  Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis , 2020, Theranostics.

[85]  P. Clézardin,et al.  The CaSR in Pathogenesis of Breast Cancer: A New Target for Early Stage Bone Metastases , 2020, Frontiers in Oncology.

[86]  B. Vincenzi,et al.  Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer , 2020, Scientific Reports.

[87]  Christopher B. Howard,et al.  Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis. , 2020, Biomaterials.

[88]  P. Bos,et al.  Preoperative embolization in surgical treatment of long bone metastasis: a systematic literature review , 2020, EFORT open reviews.

[89]  Weimin Cai,et al.  SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer , 2020, Theranostics.

[90]  E. Tanck,et al.  Patient-specific finite element computer models improve fracture risk assessments in cancer patients with femoral bone metastases compared to clinical guidelines. , 2020, Bone.

[91]  R. Midura,et al.  Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. , 2020, Biomaterials.

[92]  Xiaoyu Xu,et al.  A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[93]  I. Nagtegaal,et al.  The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival , 2019, Annals of Surgical Oncology.

[94]  C. Drake,et al.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Yilin Hu,et al.  Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells , 2019, Journal of cellular and molecular medicine.

[96]  M. Jolly,et al.  Cancer Stem Cells and Epithelial-to-Mesenchymal Transition in Cancer Metastasis. , 2019, Cold Spring Harbor perspectives in medicine.

[97]  P. Choyke,et al.  Near-Infrared Photoimmunotherapy of Cancer , 2019, Accounts of chemical research.

[98]  Y. Miyagi,et al.  GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer , 2019, International journal of cancer.

[99]  Jianjun He,et al.  The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer , 2019, BMC Cancer.

[100]  D. Welch,et al.  Defining the Hallmarks of Metastasis. , 2019, Cancer research.

[101]  S. Rahman,et al.  Parathyroid Hormone-Related Protein (PTHrP) Accelerates Soluble RANKL Signals for Downregulation of Osteogenesis of Bone Mesenchymal Stem Cells , 2019, Journal of clinical medicine.

[102]  Sakae Tanaka,et al.  Early detection of bone metastases of hepatocellular carcinoma reduces bone fracture and paralysis. , 2019, Japanese journal of clinical oncology.

[103]  A. Krämer,et al.  Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity? , 2019, Front. Oncol..

[104]  Min Zhang,et al.  Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma , 2019, Front. Immunol..

[105]  S. Ima-Nirwana,et al.  Prostate Cancer and Bone Metastases: The Underlying Mechanisms , 2019, International journal of molecular sciences.

[106]  Adrian V. Lee,et al.  Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis , 2019, Clinical Cancer Research.

[107]  M. Akhtar,et al.  Paget’s “Seed and Soil” Theory of Cancer Metastasis: An Idea Whose Time has Come , 2019, Advances in anatomic pathology.

[108]  Xinxia Peng,et al.  Circulating tumor cells exit circulation while maintaining multicellularity, augmenting metastatic potential , 2019, Journal of Cell Science.

[109]  Jacqueline A. Hall,et al.  A framework for the development of effective anti-metastatic agents , 2018, Nature Reviews Clinical Oncology.

[110]  C. Tulotta,et al.  The role of IL-1B in breast cancer bone metastasis , 2018, Endocrine-related cancer.

[111]  Yumei Zhang,et al.  Bone mesenchymal stem cell secretion of sRANKL/OPG/M-CSF in response to macrophage-mediated inflammatory response influences osteogenesis on nanostructured Ti surfaces. , 2018, Biomaterials.

[112]  J. Reagan,et al.  Mechanisms of Hypercalcemia in Non‐Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review , 2017, Clinical lymphoma, myeloma & leukemia.

[113]  F. Macedo,et al.  Bone Metastases: An Overview , 2017, Oncology reviews.

[114]  T. Bellido,et al.  Role and mechanism of action of sclerostin in bone. , 2017, Bone.

[115]  Shun-Fa Yang,et al.  Cancer metastasis: Mechanisms of inhibition by melatonin , 2017, Journal of pineal research.

[116]  Ping Yang,et al.  Prognostic effect of liver metastasis in lung cancer patients with distant metastasis , 2016, Oncotarget.

[117]  A. Mavrogenis,et al.  Palliative embolization for metastases of the spine , 2016, European Journal of Orthopaedic Surgery & Traumatology.

[118]  T. Dong,et al.  Spondin 1 promotes metastatic progression through Fak and Src dependent pathway in human osteosarcoma. , 2015, Biochemical and biophysical research communications.

[119]  R. Greil,et al.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[120]  K. Hemminki,et al.  Metastatic sites and survival in lung cancer. , 2014, Lung cancer.

[121]  N. Girard,et al.  Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). , 2014, BoneKEy reports.

[122]  F. Farrokhyar,et al.  Surgical Management of Bone Metastases: Quality of Evidence and Systematic Review , 2014, Annals of Surgical Oncology.

[123]  M. Aapro,et al.  Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[124]  M. Menon,et al.  Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. , 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[125]  F. Montorsi,et al.  Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis , 2014, The Prostate.

[126]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2013, Nature Medicine.

[127]  T. Terada,et al.  Unusual extrahepatic metastatic sites from hepatocellular carcinoma. , 2013, International journal of clinical and experimental pathology.

[128]  J. Jagannathan,et al.  Typical and atypical metastatic sites of recurrent endometrial carcinoma , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[129]  A. Mavrogenis,et al.  Embolisation of bone metastases from renal cancer , 2013, La radiologia medica.

[130]  C. Gialeli,et al.  Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. , 2012, Biochimica et biophysica acta.

[131]  A. Kajdacsy-Balla,et al.  The Lymphotactin Receptor Is Expressed in Epithelial Ovarian Carcinoma and Contributes to Cell Migration and Proliferation , 2012, Molecular Cancer Research.

[132]  T. Guise,et al.  The role of TGF-β in bone metastasis: novel therapeutic perspectives. , 2012, BoneKEy reports.

[133]  M. Menon,et al.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[134]  C. O’Brien,et al.  Osteocyte RANKL: New insights into the control of bone remodeling , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[135]  J. Schneider,et al.  Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. , 2012, Cancer research.

[136]  G. Steger,et al.  Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion , 2011, Therapeutic advances in medical oncology.

[137]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[138]  D. Lacey,et al.  Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[139]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[140]  R. Jain,et al.  CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? , 2011, Clinical Cancer Research.

[141]  T. Mueller,et al.  Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways* , 2010, The Journal of Biological Chemistry.

[142]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  P. Mantyh,et al.  Bone cancer pain , 2010, Annals of the New York Academy of Sciences.

[144]  Yao‐Hua Song,et al.  Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. , 2009, Cancer letters.

[145]  S. French,et al.  Metastatic patterns of cancers: results from a large autopsy study. , 2009, Archives of pathology & laboratory medicine.

[146]  G. Alexe,et al.  Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer? , 2009, Breast Cancer Research and Treatment.

[147]  Di Chen,et al.  PTHrP prevents chondrocyte premature hypertrophy by inducing cyclin-D1-dependent Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal degradation , 2009, Journal of Cell Science.

[148]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[149]  Yasuhiro Kobayashi,et al.  Roles of Wnt signaling in bone formation and resorption , 2008 .

[150]  R. Zarnegar,et al.  Bone metastases from differentiated thyroid carcinoma. , 2008, Endocrine-related cancer.

[151]  G. Clines,et al.  Molecular mechanisms and treatment of bone metastasis , 2008, Expert Reviews in Molecular Medicine.

[152]  M. Rogers,et al.  Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.

[153]  R. Coleman Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[154]  G. Melillo,et al.  Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.

[155]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[156]  G. Scagliotti,et al.  Management of bone metastases in cancer: a review. , 2005, Critical reviews in oncology/hematology.

[157]  Antoinette Wetterwald,et al.  Molecular and Biological Mechanisms of Bone Metastasis , 2005 .

[158]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[159]  K. Pienta,et al.  Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. , 2005, Neoplasia.

[160]  Ora Israel,et al.  Positron emission tomography and bone metastases. , 2005, Seminars in nuclear medicine.

[161]  G. Oster,et al.  The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer , 2005, Oncology.

[162]  R. Coleman Future Directions in the Treatment and Prevention of Bone Metastases , 2002, American journal of clinical oncology.

[163]  G. Karsenty,et al.  Transcription factors in bone: developmental and pathological aspects. , 2002, Trends in molecular medicine.

[164]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[165]  S. Cascinu,et al.  Novel therapeutic approaches to cancer patients with bone metastasis. , 2001, Critical reviews in oncology/hematology.

[166]  C. Silver,et al.  Incidence and Sites of Distant Metastases from Head and Neck Cancer , 2001, ORL.

[167]  R. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[168]  R. Coleman,et al.  The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. , 2001, Seminars in oncology.

[169]  T. Yoneda,et al.  Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. , 2001, Seminars in oncology.

[170]  A. Evans,et al.  Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. , 2000, Clinical radiology.

[171]  G. Andriole,et al.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.

[172]  D. Hayes,et al.  Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer , 1999, Breast Cancer Research and Treatment.

[173]  H. Plotkin,et al.  Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. , 1998, The Journal of clinical endocrinology and metabolism.

[174]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[175]  K. Harrington Orthopedic surgical management of skeletal complications of malignancy , 1997, Cancer.

[176]  D. Rosenthal Radiologic diagnosis of bone metastases , 1997, Cancer.

[177]  A. F. Stewart,et al.  Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. , 1997, The Journal of clinical endocrinology and metabolism.

[178]  R. Eastell,et al.  Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. , 1996, Cancer treatment reviews.

[179]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[180]  M. Robson,et al.  How is androgen-dependent metastatic prostate cancer best treated? , 1996, Hematology/oncology clinics of North America.

[181]  D P Dearnaley,et al.  A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[182]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[183]  R. Marcove,et al.  The management of pathological fractures. , 1965, The Journal of trauma.

[184]  Y. Liao,et al.  LncRNA TEX41 regulates autophagy by increasing Runx2 expression in lung adenocarcinoma bone metastasis. , 2023, American journal of translational research.

[185]  R. Kremer,et al.  Parathyroid Hormone-Related Protein (PTHrP): An Emerging Target in Cancer Progression and Metastasis. , 2019, Advances in experimental medicine and biology.

[186]  竹井 祥郎,et al.  Handbook of hormones : comparative endocrinology for basic and clinical research , 2016 .

[187]  H. Lepor,et al.  LHRH Agonists for the Treatment of Prostate Cancer: 2012. , 2012, Reviews in urology.

[188]  R. Kalluri,et al.  Contribution of bone microenvironment to leukemogenesis and leukemia progression , 2009, Leukemia.

[189]  K. Pienta,et al.  Expression and activation of αvβ3 integrins by SDF‐1/CXC12 increases the aggressiveness of prostate cancer cells , 2007 .

[190]  Xiyun Deng,et al.  CXCL12/CXCR4 signaling activates Akt‐1 and MMP‐9 expression in prostate cancer cells: The role of bone microenvironment‐associated CXCL12 , 2006, The Prostate.

[191]  K. Pienta,et al.  Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone , 2004, Cancer and Metastasis Reviews.

[192]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[193]  C. Denkert,et al.  Expression of cyclooxygenase 2 in human malignant melanoma. , 2001, Cancer research.

[194]  R. Rubens,et al.  Clinical course and prognostic factors following bone recurrence from breast cancer. , 1998, British Journal of Cancer.

[195]  A. F. Stewart,et al.  Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. , 1996, The Journal of clinical endocrinology and metabolism.

[196]  M. Gillespie,et al.  Parathyroid Hormone-Related Protein , 1995 .